## **ORIGINAL ARTICLE**

# Frequency of Inflammatory Myofibroblastic Tumours at Children Hospital, Lahore

MAHVISH HUSSAIN, GHAZALA HANIF, ADEEL HAMID\*, ANUM SHAHID\*\*, SAMINA ZAMAN, ZUNAIRA BASIT, SAJIDA PARVEEN, ZONAIRA RATHORE, SAADIA KHAN, AYESHA HAIDER

### **ABSTRACT**

**Objectives:** To determine the frequency of IMT in children and to correlate the histological diagnosis with the clinical features and provisional diagnosis.

**Materials and methods:** This was a retrospective analysis of all cases of IMT received in the duration of approximately two years from Apr 2010 till date at the Histopathology Department of Children's Hospital & Institute of Child Health, Lahore. Data regarding age, size and tumor histology were collected from medical records. Routine H/E staining was performed.

**Results:** A total of fifteen cases of IMT were seen in this duration. The age range was between 3 to 13 years with slight preponderance in males and predominant involvement of GIT.

**Conclusion:** IMT is a rare benign tumor seen in children. Contrary to previous studies intra-abdominal IMT is common in pediatric age group.

Key words: Inflammatory myofibroblastic tumors, benign, rare, children

## INTRODUCTION

Inflammatory myofibroblastic tumors (IMT) are rare but heterogenous group of lesions<sup>1,2</sup> due to spindle cell proliferation of disputed nosology, with a distinctive fibro inflammatory and even pseudosarcomatous appearance. Due to infiltrative pattern and cytological features, they are sometimes difficult to discriminate from malignancy<sup>1,3</sup>.

Vanik was first to define the entity histologically, termed "gastric granuloma with eosinophilic infiltration"<sup>4</sup>. It was previously referred to as plasma cell granuloma, inflammatory pseudo tumor (IPT), eosinophilic granuloma or inflammatory fibroid polyp<sup>2</sup>.

It has long been debated regarding the origin of IMT whether it was truly neoplastic or a post inflammatory process. The proposed etiologies include Epstein Barr virus (EBV), Human Herpes virus (HHV8), and over expression of interleukin 6 (IL-6). Although some other diseases like Kaposi's sarcoma and Castleman's diseases also have similar etiologies, but molecular transcription form of open reading frame (ORF) -16, K13, 72 are only expressed in IMT<sup>5</sup>. Moreover the recent research suggest that IMT is probably a neoplasm because of cytogenetic clonality, recurrent involvement of chromosomal region 2p23, occasional aggressive local behavior and metastasis of the tumor<sup>6,7</sup>.

Department of Pathology, Children Hospital & Institute of Child Health, Lahore, \*Jinnah Hospital, Lahore \*\*King Edward Medical University, Lahore

Correspondence to Dr. Mahvish Hussain, 66-C, New Muslim Town, Lahore Email mahvish66@gmail.com Cell 0332 4752537

The outlook of this disease has changed with time from a benign reactive process to a malignant neoplasm, based on the multiple case reports demonstrating recurrent and constant clonal genetic alterations<sup>8,9,10</sup>. Histologically, IMT consists of proliferation of spindle cells admixed with various amounts of lymphocyplasmacytic infiltrate<sup>1</sup>. The architectural appearances vary<sup>11</sup> with three main histological patterns: nodular fasciitis-like, fibrous histiocytoma-like, and desmoid or scar tissue-type<sup>8</sup>.

IMT generally tend to lack severe cytologic atypia and less mitosis than sarcomas and also generally tend to be negative for p53 which is positive in sarcomas<sup>11</sup>.

The differential diagnosis of IMT is a recently described lesion known as Calcifying fibrous pseudotumor (CFP), which histologically characterized by varying degrees of calcifications in addition to fibroblastic proliferation along with inflammatory cell infiltrate. It has been postulated that CFP may represent a sclerosing end stage of IMT. The final diagnosis can be helped by immunomarkers as all IMTs are diffusely positive for actin, variable positive for CD34, and focal positive for Factor XIIIa whereas CFPs are diffusely positive for factor XIIIa and negative for smooth muscle actin, musclespecific actin and CD34<sup>12</sup>. Typically the IMT is also characterized by the expression of vimentin and cytokeratins, corresponded to that of myofibroblasts along with other inflammatory markers<sup>13</sup>. ALK is only positive in 50% cases of IMT and specially in younger patients<sup>12,14</sup>.

# **MATERIALS AND METHODS**

This was a retrospective analysis of all cases of IMT received in the duration of two years from April 2010 till date at the Histopathology Department of Children's Hospital & Institute of Child Health, Lahore. Data regarding age, size and tumor histology were collected from medical records. Routine H/E staining was performed.

### **RESULTS**

A total of fifteen cases of IMT were seen in approximately two years. The age range was between 3 to 13 years with preponderance in males (M, n=10, 67% F, n=5, 33%) (Fig 1). There were nine cases of IMT involving GIT (Fig 2 ), while in four patients IMT was seen in lung, and one each in chest wall and upper pole of testis (Fig 3). Size range was between 20-120 mm (Table 1). The patients with IMT in GIT presented with the clinical features of abdominal pain, constipation, malaise and weight loss (Fig 4). There were four patients in whom the lesion was in the lungs who gave the history of respiratory distress, productive cough and yellowish sputum, while the patient with the scrotal swelling presented with enlarged testis and discomfort (Fig 5). The provisional diagnosis was mostly of either granulomatous inflammation or a malignant neoplasm.

Table 1: Size of tumour

Tumour Size(mm)	Tumour Size(mm)
120 x 110x 70	85 x 70 x 30
115 x 100 x 80	80 x 40 x 30
110 x 90 x 30	70 x 60 x 50
110 x 60 x 40	60 x 50 x 30
100 x 60 x 30	60 x 40 x 30
100 x 60 x 20	55 x 30 x30
95 x 80 x 50	50 x 30 x 30
90 x 70 x 50	

Fig 1: Gender distribution of IMT




Fig 2: Gross appearance of IMT involving mesentery of Gut.



Fig 3: Distribution of IMT in Different Sites




Fig 4: IMT of Gut showing spindle shaped cells arranged in fascicles with intervening inflammatory cells X 200





Fig 5: IMT of Testis showing dense inflammation with proliferating fibroblasts X 300



## DISCUSSION

IMT is a rare benign tumor that can be seen in various organs. Local recurrences and malignant transformation have been reported in a small subset of patients, but these generally tend to occur where complete resection has been impossible<sup>1</sup>.

IMT is a challenging lesion with respect to classification, differential diagnosis, and biologic potential. It is usually seen in young people and of unknown etiology<sup>15,16</sup> affecting females more than males as it has also been observed by Coffin et al<sup>3</sup>. This is in contrast to the present study in which majority of patients were males (67%). IMT can be seen in any part of the body<sup>1,2</sup> most commonly involving lungs<sup>3</sup> and orbit<sup>17</sup>. Urinary bladder is the most common organ involved in the genitourinary tract while kidneys, renal pelvis and ureter are rarely involved<sup>10</sup>. IMT occurring at intra-abdominal sites in children have rarely been described. Similar findings were observed by Yimyaem et al and Imtiaz Wani who noticed IMT as very rare lesion in the gut 18,19. However their findings are in contrast to the present study as we diagnosed nine cases (60%) of IMT in GIT alone. Coffin et al also observed that most of the IMT were present in GIT and pelvis followed by head and neck, trunk and extremities<sup>3</sup>.

These tumors can also be present in the thoracic cavity although cardiac IMT are very rare as Burke et al observed 10 intracavitary polypoid myofibroblastic proliferations in children and young adults with the male to female ratio of 6:4 and a mean age of 10 years<sup>20</sup>, whereas we observed four cases (26.7%) of IMT in the lung.

The tumors in the present study ranged in size from 20-120mm. Coffin et al also observed the lesions of IMT in the range of 10-170mm<sup>3</sup>.

The clinical features of these patients depend upon the sites involved. However they often present

with fever of unknown origin and other vague nonspecific symptoms. Usually it has a benign course and in most cases it is a slow growing, locally confined tumor with less metastatic potential. However, there are some predictors for aggressive behavior and metastatic potential of IMT which include presence of ganglion like cells, cellular atypia, aneuploidy, and p53 over expression 15,16.

According to a study conducted by Montazeri et al 108 myofibroblastic tumors were seen in a 25-year period. Based on clinicopathologic criteria, 82(76%) were regarded as benign, 14(13%) as borderline, and 12(11%) ias malignant with the recurrence rate of 16%. The average age at diagnosis for the entire series was 7 years with a male/female ratio of 1.8:1. The most frequent topographic site was the extremities 48(44%), followed by the trunk 31(29%) and the head and neck region 27(25%). Virtually 50% (51 tumors) of cases were diagnosed during the first year of life, and 73(71%) occurred in the first decade<sup>21</sup>.

Biselli et al as well as Morotti et al also observed local recurrence or distant metastases in their studies<sup>22,23</sup>. The follow-up of the patients was beyond the scope in the present study; however the clinical diagnosis of the cases was of either granulomatous inflammation or suspicion of malignant neoplasms.

## CONCLUSION

IMT is a rare benign tumor commonly seen in children. Contrary to previous studies in paediatric age group intra-abdominal IMT is more common as well as preponderance in males.

## REFERENCES

- Inflammatory pseudotumor of the Kidney. Selvan DR, Philip J, Manikandan R, Helliwell TR, Lamb GHR and Desmond AD. World Journal of Surgical Oncology 2007; 5:106
- Retroperitoneal inflammatory myofibroblastic tumor. Attili SVS, Chandra CR, Hemant DK, Bapsy PP, RamaRao C and Anupama G. World Journal of Surgical Oncology 2005; 3:66
- Coffin CM, Watterson J, Priest JR, Dehner LP: Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinic pathologic and immuno-histochemical study of 84 cases. Am J Surg Pathol 1995;19:859-72
- 4. VANIK, J. Gastric submucosal granuloma with Eosinophilic infiltration. Am. 7. Path., 125, 397-412.
- Gomez-Roman JJ, Sanchez-Velasco P, Ocejo-Vinyals G, Hernandez-Nieto E, Leyva-Cobian F, Val-Bernal JF: Human herpesvirus-8 genes are expressed in pulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). Am J Surg Pathol 2001; 25:624-9.

- Pungpapong S, Geiger XJ, Raimondo M: Inflammatory myofibroblastic tumor presenting as a pancreatic mass: a case report and review of the literature. JOP 2004;5:360-7.
- Coffin CM, Dehner LP, Meis-Kindblom JM: Inflammatory myofibroblastic tumor, inflammatory fibrosarcoma, and related lesions: an historical review with differential diagnostic considerations. Semin Diagn Pathol 1998;15:102-10
- Freeman A, Geddes N, Munson P, Joseph J, Ramani P, Sandison A, Fisher C, Parkinson MC: Anaplastic lymphoma kinase (ALK 1) staining and molecular analysis in inflammatory myofibroblastic tumors of the bladder: a preliminary clinicopathological study of nine cases and review of the literature. Mod Pathol 2004;17:765-71
- Biselli R, Boldrini R, Ferlini C, Boglino C, Inserra A, Bosman C: Myofibroblastic tumors: neoplasias with divergent behavior. Ultrastructural and flow cytometric analysis. Pathol Res Pract 1999;195:619-32.
- Kapusta LR, Weiss MA, Ramsay J, Lopez-Beltran A, Srigley JR: Inflammatory Myofibroblastic Tumors of the Kidney – A clinicopathologic and Immunohistochemical Study of 12 cases. Am J Surg Pathol 2003; 27:658-66
- Gelb AB, Simmons ML, Weidner N: Solitary fibrous tumor involving the renal capsule. Am J Surg Pathol 1996;20:1288-95
- Calcifying Fibrous Pseudotumor versus Inflammatory Myofibroblastic Tumor: A Histological and Immunohistochemical Comparison. Kalisha A. Hill, Frank Gonzalez-Crussi, and Pauline M. Chou. Mod Pathol 2001:14:784-90
- Sastre-Garau X, Couturier J, Derre J, Aurias A, Klijanienko J, Lagace R: Inflammatory myofibroblastic tumour (inflammatory pseudotumour) of the breast. Clinicopathological and genetic analysis of a case with evidence for clonality. J Pathol 2002;196:97-102
- Cook JR, Dehner LP, Collins MH, Ma Z, Morris SW, Coffin CM, Hill DA: Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor:

- a comparative immunohistochemical study. Am J Surg Pathol 2001:25:1364-71
- Hussong JW, Brown M, Perkins SL, Dehner LP, Coffin CM: Comparison of DNA ploidy, histological and immunohistochemical findings with clinical outcome in inflammatory myofibroblastic tumors. Mod Pathol 1999:12:279-86.
- Imperato JP, Folkman J, Sagerman RH, Cassady JR:Treatment of plasma cell granuloma with radiation therapy: a report of two cases and a review of the literature. Cancer 1986;57:2127-9
- Inflammatory Pseudotumor. Narla LD, Newman B, Spottswood SS, Narla S, and Kolli R.\_RadioGraphics 2003; 23:719-29.
- Imtiaz ani. Inflammatory Myofibroblastic Tumor of Mesentery: A Case Report. Journal of Gastrointestinal Cancer 2007;38(2-4):115-8
- Yimyaem P, Saranrittichai S, Sinawat P, Dhiensiri T. Inflammatory myofibroblastic tumor of the small intestine: a case report of a 2 month-old infant. J Med Assoc Thai 2009;92(1):114-9
- Cardiac Inflammatory Myofibroblastic Tumor: A "Benign" Neoplasm That May Result in Syncope, Myocardial Infarction, and Sudden Death. Burke A, Li L, Kling E, Kutys R, Virmani R, Miettinen M. Am J Surg Pathol. 2007 Jul;31(7):1115-22
- Montazeri V, Sokouti M, Heidarnazhad H, Mirri M. Inflammatory Pseudotumor Of The Lung:Report Of Four Adult Cases. A case report. Arch Iranian Med 2005;8(4):314–8
- Inflammatory myofibroblastic tumor (Inflammatory pseudotumor): DNA flow cytometric analysis of nine pediatric cases. Biselli R, Ferlini C, Fattorossi A, Boldrini R, Bosman C, Cancer,1998;77(4):778-84
- 23. Pediatric Inflammatory Myofibroblastic Tumor With Late Metastasis to the Lung: Case Report and Review of the Literature. Morotti RA, Legman MD, Kerkar N, Pawel BR, Sanger WG and Coffin CM. Pediatric and Developmental Pathology. Pediatric and Developmental Pathology, 2005;8(2):224-9